TELA Bio, Inc. provided revenue guidance for the full year 2024. Full year 2024 revenue is projected to range from $74.0 million to $76.0 million, representing growth of 27% to 30% over full year 2023.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.8 USD | -2.44% | +3.67% | -27.49% |
04-15 | TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR | CI |
03-22 | Piper Sandler Adjusts Price Target on TELA Bio to $12 From $15, Maintains Overweight Rating | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.49% | 118M | |
-4.66% | 183B | |
-1.01% | 108B | |
-4.20% | 67.51B | |
+2.68% | 50.67B | |
+9.12% | 44.7B | |
+2.41% | 40.95B | |
+4.13% | 26.71B | |
+3.31% | 26.8B | |
+12.66% | 24.62B |
- Stock Market
- Equities
- TELA Stock
- News TELA Bio, Inc.
- TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2024